PL3389717T3 - Terapia neoadjuwantowa raka pęcherza moczowego - Google Patents

Terapia neoadjuwantowa raka pęcherza moczowego

Info

Publication number
PL3389717T3
PL3389717T3 PL16819894.3T PL16819894T PL3389717T3 PL 3389717 T3 PL3389717 T3 PL 3389717T3 PL 16819894 T PL16819894 T PL 16819894T PL 3389717 T3 PL3389717 T3 PL 3389717T3
Authority
PL
Poland
Prior art keywords
bladder cancer
neoadjuvant therapy
neoadjuvant
therapy
bladder
Prior art date
Application number
PL16819894.3T
Other languages
English (en)
Inventor
Kjetil Hestdal
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Publication of PL3389717T3 publication Critical patent/PL3389717T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/061—Bladder and/or urethra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A61N2005/0629—Sequential activation of light sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16819894.3T 2015-12-17 2016-12-19 Terapia neoadjuwantowa raka pęcherza moczowego PL3389717T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522309.2A GB201522309D0 (en) 2015-12-17 2015-12-17 Use
PCT/EP2016/081803 WO2017103283A1 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer

Publications (1)

Publication Number Publication Date
PL3389717T3 true PL3389717T3 (pl) 2025-06-09

Family

ID=55311159

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16819894.3T PL3389717T3 (pl) 2015-12-17 2016-12-19 Terapia neoadjuwantowa raka pęcherza moczowego

Country Status (13)

Country Link
US (2) US10556010B2 (pl)
EP (1) EP3389717B9 (pl)
JP (1) JP6926086B2 (pl)
KR (1) KR102787188B1 (pl)
CN (2) CN108601836A (pl)
AU (1) AU2016372573B2 (pl)
BR (1) BR112018012009B1 (pl)
DK (1) DK3389717T3 (pl)
ES (1) ES3015668T3 (pl)
FI (1) FI3389717T3 (pl)
GB (1) GB201522309D0 (pl)
PL (1) PL3389717T3 (pl)
WO (1) WO2017103283A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522311D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
US11266619B2 (en) 2017-12-01 2022-03-08 Sbi Pharmaceuticals Co., Ltd. Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
KR102441358B1 (ko) 2020-09-14 2022-09-06 주식회사 아파트엔 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템
KR20250154511A (ko) 2023-03-07 2025-10-28 포토큐어 에이에스에이 방광암 치료
WO2026052815A1 (en) 2024-09-05 2026-03-12 Photocure Asa Use of hal in a method for predicting bladder cancer immunotherapy response

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
DE122006000051I1 (de) 1995-03-10 2007-01-04 Photocure Asa Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010142457A1 (en) 2009-06-11 2010-12-16 Photocure Asa Semi-solid compositions and pharmaceutical products
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
ES2742379T3 (es) 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
US8927761B2 (en) 2012-06-28 2015-01-06 Photocure Asa Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same
RU2635563C2 (ru) * 2012-08-03 2017-11-14 ФотоКьюэр АСА Соединения
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
CN109010850B (zh) * 2018-08-01 2021-10-22 上海师范大学 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用

Also Published As

Publication number Publication date
WO2017103283A1 (en) 2017-06-22
CN119345359A (zh) 2025-01-24
GB201522309D0 (en) 2016-02-03
KR102787188B1 (ko) 2025-03-25
FI3389717T3 (fi) 2025-04-08
RU2018124868A (ru) 2020-01-27
EP3389717B1 (en) 2025-02-19
CA3008551A1 (en) 2017-06-22
JP6926086B2 (ja) 2021-08-25
JP2018537514A (ja) 2018-12-20
AU2016372573A1 (en) 2018-07-12
BR112018012009B1 (pt) 2023-12-19
KR20180094987A (ko) 2018-08-24
EP3389717A1 (en) 2018-10-24
ES3015668T3 (en) 2025-05-07
BR112018012009A2 (pt) 2018-12-04
US10556010B2 (en) 2020-02-11
EP3389717B9 (en) 2025-07-23
CN108601836A (zh) 2018-09-28
DK3389717T3 (da) 2025-03-31
US20200155683A1 (en) 2020-05-21
US20180369379A1 (en) 2018-12-27
AU2016372573B2 (en) 2022-07-21
RU2018124868A3 (pl) 2020-05-13
US11311620B2 (en) 2022-04-26

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination for cancer treatment
IL254705A0 (en) Combination therapy for cancer
IL259017A (en) Cancer cure is intended
ZA201702382B (en) Combination therapy for cancer
IL255060A0 (en) Combined treatment for cancer
PT3423087T (pt) Terapia de cpombinação contra o cancro
SMT201800303T1 (it) Trattamenti per il cancro
IL249898A0 (en) Combined cancer treatment
IL246761A0 (en) Combined cancer treatment
IL258671A (en) A therapeutic agent for breast cancer
DK3389717T3 (da) Neoadjuvansterapi for blærekræft
PL3390448T3 (pl) Terapia dopęcherzowa raka pęcherza moczowego
GB201519734D0 (en) Cancer therapy
GB201704909D0 (en) Cancer therapy
IL259097A (en) Combination therapy for cancer
GB201711855D0 (en) Cancer therapy
HRP20210383T8 (hr) Kombinirana terapija za rak
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy
GB201706046D0 (en) Cancer therapy
GB201700772D0 (en) Cancer therapy
GB201511609D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy
GB201601248D0 (en) Cancer therapy